Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Sub-study of 54 males with HIV who had 2 doses of AZ vaccine, found no difference in magnitude or persistence of SARS-CoV-2 spike-specific humoral or cellular responses vs vaccinated subjects without HIV, supporting vaccination for those well controlled on antiretroviral therapy.

Source:

The Lancet HIV